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R A P I D  R E C O M M E N DAT I O N S
Patent foramen ovale closure, antiplatelet 
therapy or anticoagulation therapy alone 
for management of cryptogenic stroke?  
A clinical practice guideline
Ton Kuijpers,1 Frederick A Spencer,2 Reed A C Siemieniuk,3  4 Per O Vandvik,5  6  
Catherine M Otto,7 Lyubov Lytvyn,2 Hassan Mir,2 Albert Y Jin,8 Veena Manja,9  
Ganesan Karthikeyan,10 Elke Hoendermis,11 Janet Martin,12 Sebastian Carballo,13  
Martin O’Donnell,14 Trond Vartdal,15 Christine Baxter,16 Bray Patrick-Lake,17 Joanie Scott,18 
Thomas Agoritsas,3  19 Gordon Guyatt2  3
Options for the secondary prevention of stroke in 
patients younger than 60 years who have had a cryp‑
togenic ischaemic stroke thought to be secondary to 
patent foramen ovale (PFO) include PFO closure (with 
antiplatelet therapy), antiplatelet therapy alone, or 
anticoagulants. International guidance and practice 
differ on which option is preferable.
The BMJ Rapid Recommendations panel used a 
linked systematic review1 triggered by three large 
randomised trials published in September 2017 that 
suggested PFO closure might reduce the risk of ischae‑
mic stroke more than alternatives.2‑4 The panel felt that 
the studies, when considered in the context of the full 
body of evidence, might change current clinical prac‑
tice.5 The linked systematic review finds that PFO clo‑
sure prevents recurrent stroke relative to antiplatelet 
therapy, but possibly not relative to anticoagulants, 
and is associated with procedural complications and 
persistent atrial fibrillation.1 The review also presents 
evidence regarding the role of anticoagulants or anti‑
platelet therapy when PFO closure is not acceptable or 
is contraindicated.
This expert panel make a
•   Strong recommendation in favour of PFO 
closure plus antiplatelet therapy compared with 
antiplatelet therapy alone
•   Weak recommendation in favour of PFO closure plus 
antiplatelet therapy compared with anticoagulants
•   Weak recommendation in favour of anticoagulants 
compared with antiplatelet therapy.
The largest challenge in making our recommendation 
was the low quality evidence for the comparisons that 
included anticoagulants. We summarised all the high‑
est quality available evidence separately for antiplatelet 
therapy and anticoagulants because the evidence sug‑
gests it is likely their effectiveness and adverse effects 
differ, and clinicians and patients should be aware of 
these likely differences. Our panel believes that the 
mechanism of benefit with PFO closure is prevention 
of venous clots crossing the PFO. Anticoagulants are 
likely to be substantially more effective in preventing 
such clots from initially arising than antiplatelet agents.
Box 1 shows the articles and linked evidence in 
this Rapid Recommendation package. The main 
infographic presents the recommendations as three 
paired comparisons, together with an overview of 
the absolute benefits and harms informing each 
re commendation, according to the GRADE method‑
ology.
Current practice
Management options for those with patent foramen 
ovale (PFO) and cryptogenic stroke
Typically, patients with cryptogenic stroke and PFO have 
three treatment options to reduce the risk of future stroke:
(a) Closure of the PFO with subsequent antiplatelet 
therapy that may be continued indefinitely or 
discontinued some months after PFO closure
(b) Antiplatelet therapy alone
(c) Anticoagulant therapy alone.
WHAT YOU NEED TO KNOW
•   The recommendations apply to patients 
under 60 years old with patent foramen 
ovale (PFO) who have had a cryptogenic 
ischaemic stroke, when extensive workup for 
other aetiologies of stroke is negative
•   For patients who are open to all options, 
we make a weak recommendation for PFO 
closure plus antiplatelet therapy rather than 
anticoagulant therapy
•   For patients in whom anticoagulation is 
contraindicated or declined, we make a 
strong recommendation for PFO closure 
plus antiplatelet therapy versus antiplatelet 
therapy alone
•   For patients in whom closure is 
contraindicated or declined, we make a weak 
recommendation for anticoagulant therapy 
rather than antiplatelet therapy.
•   Further research may alter the 
recommendations that involve anticoagulant 
therapy
Full author details can be found at 
the end of the article
Correspondence to: T Kuijpers 
t.kuijpers@nhg.org
Cite this as: BMJ 2018;362:k2515
doi: 10.1136/bmj.k2515
This BMJ Rapid Recommendation 
article is one of a series that 
provides clinicians with trustworthy 
recommendations for potentially 
practice changing evidence. 
BMJ Rapid Recommendations 
represent a collaborative effort 
between the MAGIC group (www.
magicproject.org) and The 
BMJ. A summary is offered here 
and the full version including 
decision aids is on the MAGICapp 
(www.magicapp.org), for all 
devices in multilayered formats. 
Those reading and using these 
recommendations should consider 
individual patient circumstances, 
and their values and preferences 
and may want to use consultation 
decision aids in MAGICapp to 
facilitate shared decision making 
with patients. We encourage 
adaptation and contextualisation 
of our recommendations to local or 
other contexts. Those considering 
use or adaptation of content may 
go to MAGICapp to link or extract 
its content or contact The BMJ for 
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Comparison 1
Comparison of benefits and harms
The panel believes that there is probably substantial 
benefit in stroke reduction after PFO closure, which will be 
very important to all or almost all patients. This is likely to 
outweigh important undesirable consequences, like 
procedure or device related events and persistent atrial 
fibrillation
Preferences and values Applicability
The applicability of these findings to patients over 60 
and those with traditional cerebrovascular risk factors 
(e.g. diabetes, hypertension, and hyperlipidemia) is 
more uncertain. In older patients, fewer cryptogenic 
strokes are caused by paradoxical emboli, so we expect 














Favours PFO closure Favours antiplatelets
StrongStrong WeakWeak
We recommend PFO closure followed by antiplatelet 
therapy over antiplatelet therapy alone.
No key practical issuesProcedure takes under 2 hours
In-hospital stay is usually one day
Most activities can be resumed within a few days




See all outcomesSee patient decision aids
Ischaemic stroke Moderate More100
Risk of Bias No serious concerns
Imprecision Serious
Indirectness No serious concerns
Inconsistency No serious concerns
Publication bias No serious concerns
Evidence qualityEvents per 1000 people
PFO closure plus antiplatelet 
therapy probably results in a 




Risk of Bias No serious concerns
Imprecision Serious
Indirectness No serious concerns
Inconsistency No serious concerns
Publication bias No serious concerns
There is probably little 
or no difference in death
9
Major bleeding Moderate More14
Risk of Bias No serious concerns
Imprecision Serious
Indirectness No serious concerns
Inconsistency No serious concerns
Publication bias No serious concerns
There is probably little or no 
difference in major bleeding
7
18 fewerPersistent AF       or flutter Moderate More5
Risk of Bias Serious
Imprecision No serious concerns
Indirectness No serious concerns
Inconsistency No serious concerns
Publication bias No serious concerns
PFO closure plus antiplatelet 
therapy probably increases 
persistent atrial fibrillation or flutter
23
36 fewerDevice-related adverse events High More0
Risk of Bias No serious concerns
Imprecision No serious concerns
Indirectness No serious concerns
Inconsistency No serious concerns
Publication bias No serious concerns
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Comparison of benefits and harms
Favours PFO closure Favours anticoagulants
StrongStrong WeakWeak
We suggest PFO closure followed by antiplatelet therapy over 





The panel felt that many patients would not want the 
long-term bleeding risk from anticoagulation therapy, 
which will usually outweigh the probable risk of procedure 
or device related events and persistent atrial fibrillation 
with PFO closure
Preferences and values Applicability
The applicability of these findings to patients over 60 
and those with traditional cerebrovascular risk factors 
(e.g. diabetes, hypertension, and hyperlipidemia) is 
more uncertain. In older patients, fewer cryptogenic 
strokes are caused by paradoxical emboli, so we expect 






Procedure takes under 2 hours
In-hospital stay is usually one day
Most activities can be resumed within a few days
Full recovery within a few weeks
Initial frequent testing required to achieve appropriate dose
Periodic testing required while taking medication
See all outcomesSee patient decision aids
Ischaemic stroke Low More29
Risk of Bias No serious concerns
Imprecision Very serious
Indirectness No serious concerns
Inconsistency No serious concerns
Publication bias No serious concerns
Evidence qualityEvents per 1000 people
There may be little or no 







Risk of Bias No serious concerns
Imprecision Serious
Indirectness No serious concerns
Inconsistency No serious concerns
Publication bias No serious concerns
There is probably little 
or no difference in death
9
Major bleeding Moderate More27
Risk of Bias No serious concerns
Imprecision Serious
Indirectness No serious concerns
Inconsistency No serious concerns
Publication bias No serious concerns
PFO closure plus antiplatelet 
therapy probably decreases 
major bleeding
7 20 fewer
18 fewer Moderate More5
Risk of Bias Serious
Imprecision No serious concerns
Indirectness No serious concerns
Inconsistency No serious concerns
Publication bias No serious concerns
PFO closure plus antiplatelet 
therapy probably increases 
persistent atrial fibrillation
23
36 fewerDevice-related adverse events High More0
Risk of Bias No serious concerns
Imprecision No serious concerns
Indirectness No serious concerns
Inconsistency No serious concerns
Publication bias No serious concerns
PFO closure can lead to device- or 
procedure-related adverse events
36
Persistent AF       or flutter
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Comparison 3
Comparison of benefits and harms
The panel felt that the possible decrease in ischemic stroke with anticoagulants would be more important 
to most patients than the probable increase in major bleeding. We expect variability in how patients might 
value these outcomes. Shared decision making may help establish what matters most to each patient
Preferences and values
Within 5 years




See all outcomesSee patient decision aids
Ischaemic stroke Low More100
Risk of Bias No serious concerns
Imprecision Very serious
Indirectness No serious concerns
Inconsistency No serious concerns
Publication bias No serious concerns
Evidence qualityEvents per 1000 people
Anticoagulation may decrease 
ischaemic stroke
No important differenceDeath Low More3
Risk of Bias No serious concerns
Imprecision Very serious
Indirectness No serious concerns
Inconsistency No serious concerns
Publication bias No serious concerns
There may be little or no 
difference in death
13
Major bleeding Moderate More
Risk of Bias No serious concerns
Imprecision Serious
Indirectness No serious concerns
Inconsistency No serious concerns




Pulmonary embolism Moderate More5
Risk of Bias No serious concerns
Imprecision No serious concerns
Indirectness Serious
Inconsistency No serious concerns
Publication bias No serious concerns
There is probably little 
or no difference in 
pulmonary embolism.
1 No important difference
71 fewer29
12 fewer 14
Initial frequent testing required to achieve appropriate dose
Periodic testing required while taking medication









We suggest anticoagulation over antiplatelet therapy.
Discuss both options with each patient.

APLOAC
Find recommendations, evidence summaries and 
consultation decision aids for use in your practice
© 2017 BMJ Publishing group Ltd.
See an interactive version
of this graphic online http://bit.ly/BMJrrpfo
Disclaimer: This infographic is not a clinical decision aid. This information is provided without any representations, conditions or warranties that it is accurate or up to date. BMJ and its licensors assume no responsibility 
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directly into the arterial circulation and cause a stroke—
a phenomenon known as a paradoxical embolism.20 21 
This can be characterised with echocardiography (box 3).
The evidence
The linked systematic review reports the relative and the 
absolute effects of PFO closure followed by antiplate-
let therapy versus antiplatelet therapy alone or versus 
anticoagulation and the effect of anticoagulation versus 
antiplatelet therapy in patients with cryptogenic stroke 
and PFO.1 Figure 2 provides an overview of the number 
and types of patients included, the study funding, and 
patient involvement.
We conducted a network meta-analysis combining 
direct evidence (from studies of management in people 
with cryptogenic stroke comparing at least two of the 
three options) with indirect evidence (inferring benefits 
Most current guidelines recommend against routine 
closure of the PFO in patients with cryptogenic stroke and 
instead recommend antiplatelets or anticoagulation (the 
latter if indicated for another reason) (box 2).6-9
Identification of cryptogenic stroke
In about a third of patients in the general population who 
are diagnosed with an acute ischaemic stroke, investiga-
tion finds no clear cause; it is cryptogenic.10 Clinicians 
reach the diagnosis by ruling out alternative reasons for 
stroke through prolonged rhythm monitoring to exclude 
atrial fibrillation; transoesophageal echocardiography 
or alternative imaging of the aorta and left atrial append-
age to rule out aortic atherothrombosis or left atrial clot; 
and carotid ultrasonography, computed tomography, or 
magnetic resonance imaging to rule out cerebrovascular 
disease.
Patients diagnosed with cryptogenic stroke are less 
likely to have classic risk factors for atheroembolic 
stroke such as older age, hypertension, hyperlipidaemia, 
and diabetes.11 They are more likely to have a PFO than 
patients in the general population.12
Implications of a patent foramen ovale (PFO)
The presence of a PFO does not result in an identifiable 
increased risk of stroke in the general population.13-15 Many 
meta-analyses have addressed whether closure of a PFO 
reduces the long term risk of subsequent stroke,12 16-18 but 
most have concluded that there is insufficient evidence.6
PFO is a communication between the right and left 
atrium, typically diagnosed by transthoracic echocar-
diography with observed flow between the left to right 
atrium by colour Doppler ultrasonography.19 If the 
shunt direction reverses, this communication may allow 
a venous thrombus or right atrial thrombus to travel 
Box 1 | Linked resources for this BMJ Rapid 
Recommendations cluster
• Kuijpers T, Spencer FA, Siemieniuk RAC, et al. Patent 
foramen ovale closure, antiplatelet therapy or 
anticoagulation therapy alone for management of 
cryptogenic stroke? A clinical practice guideline. BMJ 
2018;362:k2515
 – Summary of the results from the Rapid 
Recommendation process
• Mir H, Siemieniuk R, Ge L, et al. Percutaneous closure plus 
antiplatelet therapy versus antiplatelet or anticoagulation 
therapy alone in patients with patent foramen ovale and 
cryptogenic stroke: a systematic review and network 
meta-analysis incorporating complementary external 
evidence. BMJ Open 2018;0:e023761. doi:10.1136/
bmjopen-2018-023761
 – Review and network meta-analysis of all available 
randomised trials that assessed PFO closure as adjunct 
treatment to antiplatelet versus antiplatelet therapy 




 – Expanded version of the results with multilayered 
recommendations, evidence summaries, and decision 
aids for use on all devices
Box 2 | Current guidance for closure of patent foramen 
ovale (PFO) in patients with PFO and cryptogenic stroke
American Academy of Neurology 20176
• PFO v medical therapy alone—Clinicians must counsel 
patients considering percutaneous PFO closure that having 
a PFO is common in the general population; it is impossible 
to determine with certainty whether their PFO caused their 
stroke or transient ischaemic attack; the effectiveness of 
the procedure for reducing stroke risk remains uncertain; 
and the procedure is associated with relatively uncommon, 
yet potentially serious, complications
• Anticoagulation v antiplatelet—In the absence of another 
indication for anticoagulation, clinicians may routinely 
offer antiplatelet drugs instead of anticoagulation to 
patients with cryptogenic stroke and PFO
American Heart Association/American Stroke Association7
• For patients with an ischaemic stroke or transient ischaemic 
attack and a PFO who are not undergoing anticoagulation 
therapy, antiplatelet therapy is recommended
• For patients with an ischaemic stroke or transient 
ischaemic attack and both a PFO and a venous source 
of embolism, anticoagulation is indicated depending 
on stroke characteristics. When anticoagulation is 
contraindicated, an inferior vena cava filter is reasonable
• For patients with a cryptogenic ischaemic stroke or 
transient ischaemic attack and a PFO without evidence 
for deep vein thrombosis, available data do not support a 
benefit for PFO closure
• In the setting of PFO and deep vein thrombosis, PFO closure 
by a transcatheter device might be considered depending 
on the risk of recurrent deep vein thrombosis
NICE 20138
• Evidence on the safety of percutaneous closure of PFO to 
prevent recurrent cerebral embolic events shows serious 
but infrequent complications. Evidence on its efficacy is 
adequate. Therefore, this procedure may be used with 
normal arrangements for clinical governance, consent, 
and audit
Netherlands Society of Cardiology 20169
• Closure of a PFO is not beneficial in unselected patients 
with transient ischaemic attack or cryptogenic stroke
• Closure of a PFO should be considered in patients with 
transient ischaemic attack or cryptogenic stroke and a Risk 
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and harms of two alternatives through relative effects 
on a third option) to obtain more informative estimates 
of effect. The paucity of data regarding anticoagulation 
for this intervention resulted in a sparsely populated 
network with low certainty evidence. The estimates of 
relative effect of PFO closure versus anticoagulation were 
extremely imprecise. Only 353 patients were randomised 
to PFO closure versus anticoagulation, and 405 patients 
to anticoagulation versus antiplatelet agents, and events 
were infrequent. Therefore, to obtain more precise esti-
mates, we performed additional analyses based on indi-
rect evidence.
The systematic review also reports indirect evidence, 
from participants who did not have PFO and cryptogenic 
stroke, but venous thromboembolism.23 This evidence 
was used to inform the effects of anticoagulation versus 
on stroke. Similarly, for the outcome of major bleeding, 
we performed additional analyses based on indirect 
evidence comparing anticoagulation with antiplatelet 
therapy for several non-PFO associated indications.1
Specific groups of PFO patients with cryptogenic stroke
We hypothesised that studies including more patients 
with larger shunt sizes, and those that included more 
patients treated with anticoagulants, would demonstrate 
larger effects. A separate systematic review24 reported that 
PFO closure, compared with any medical therapy, was 
more effective in patients with moderate or large size 
shunts. However, the same clinical trials that included 
more patients with larger shunts also included fewer 
patients who were prescribed anticoagulants in the medi-
cal therapy arm; this confounding makes it impossible 
to sort out which association (if either) was responsible 
for the larger effect. Therefore, the shunt size subgroup 
effect has low credibility (for more details see the linked 
systematic review).1
Box 3 | Details of echocardiographic diagnosis, risk profile, 
and patent foramen ovale (PFO) procedure planning
• Which route—Transesophageal echocardiography has a 
higher sensitivity for detection of a PFO compared with 
transthoracic imaging and is recommended in younger 
adults with unexplained cerebrovascular events
• Work-up of cryptogenic stroke—In addition to detection 
of PFO, rarer causes of embolic events include an atrial 
septal defect, cardiac tumours (such as myxoma or 
papillary fibroelastoma), bacterial or non-bacterial valve 
vegetations, and atrial thrombi
• Detection of PFO—Microbubbles enter the right atrium, 
and, if a PFO is present, they pass into the left atrium within 
a few beats of appearance in the right atrium. Although 
shunting usually is predominantly left to right, there is 
some right to left shunting as the relative pressures in the 
two chambers change during the cardiac cycle and with 
respiration
 – Sensitivity of saline contrast for detection of a PFO is 
increased by asking the patient to perform a Valsalva 
manoeuvre, which transiently increases right atrial 
pressure
 – Estimating the size of a PFO based on the amount of 
contrast seen in the left atrium may be unreliable22
• Those with PFO at greater risk—An atrial septal aneurysm, 
defined as excessive bulging of atrial septal fossa ovalis, 
is often associated with septal fenestrations and may be a 
marker of increased embolic risk
• Ahead of planned PFO closure—Transeophageal 
echocardiography is recommended for more detailed 










Four trials were commercially sponsored
One study received governmental funding
Two studies received a grant form a non-profit research foundation
One study received no funding
NUMBER OF TRIALS 6
NUMBER OF PATIENTS 3560 
DATA SOURCES
Use this information to gauge how
similar your patients’ conditions are
to those of people studied in the trials 
Antiplateletsor Anticoagulantsor
PATIENT CHARACTERISTICS














































0 10 20 40 5030





    (% men)   
SMOKER
    (% of patients)   
DIABETES
    (% of patients)   
HYPERTENSION
    (% of patients)   
HYPERLIPIDEMIA
    (% of patients)   
FOLLOW-UP TIME
    (years)   







3 trials used 100% Amplatzer
1 trial 100% STARflex
1 trial 61% Cardioform and 39% 
Gore Helex Septal Occluder
1 trial 52% Amplatzer and 48%





TYPE OF PFO CLOSURE DEVICE
NUMBER OF TRIALS 3
NUMBER OF PATIENTS 503 
PATIENT CHARACTERISTICS












































0 10 20 40 5030







NUMBER OF TRIALS 1
NUMBER OF PATIENTS 353 
PATIENT CHARACTERISTICS
0 400200 800600 1000
45 50 55 65 7060
59
0 10 20 40 5030
52% Amplatzer and 48% other 
types of devices 1
TYPE OF PFO CLOSURE DEVICE
353
40 44 48 52 56 60
43.4
29.0
0 5 10 20 2515
2.6
10.8
0 15 30 60 7545
14.0
0 10 20 40 5030








Patients who were treated with antiplatelet in most cases received aspirin but
may have received another antiplatelet agent or a combination
EXCLUSION CRITERIA






IP No trials reported involving patients 
in design or conduct
Patients who were treated with anticoagulant in most cases received warfarin
but may have received direct oral anticoagulants (DOAC)
Fig 2 |  Characteristics of patients and trials included in systematic review of the effects of 
percutaneous closure followed by antiplatelet therapy versus antiplatelet or anticoagulation 
therapy alone in patients with patent foramen ovale (PFO) and cryptogenic stroke. Evidence used 
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We were unable to stratify our analyses and recom-
mendations by type or generation of PFO closure device 
because of the limitations in published data and small 
subset sample sizes.
Procedure or device related adverse events
Procedure or device related adverse events included 
vascular complications (1%), conduction abnormalities 
(1%), device dislocation (0.7%), and device thrombosis 
(0.5%). Less serious adverse events such as minor bleed-
ing and supraventricular tachycardia were inconsistently 
reported; the panel judged them as important, however, 
and took them into account in making recommendations.
Values and preferences
No studies had relevant information on values and pref-
erences. We screened 455 titles and abstracts, and six 
full text articles. Appendix 1 on bmj.com presents our 
systematic review of the limited evidence. Three people 
with experience of living with cryptogenic stroke and PFO 
provided input regarding the choice of outcomes. 
Understanding the recommendations
Absolute benefits and harms
The panel considered PFO closure plus antiplatelets bet-
ter than antiplatelet agents alone. This is a strong recom-
mendation because the absolute differences and patient 
preferences were aligned to place a high value on stroke 
prevention. Patients are likely to find an absolute reduc-
tion of stroke with PFO closure of 8.7% at five years very 
important. Although 3.6% will experience an adverse 
event, such events, including 1.8% increase in atrial 
fibrillation, do not usually result in long term disability 
and so were considered less important.
The possible small reduction in stroke and decreased 
bleeding risk with PFO closure versus anticoagulants 
alone mandated a weak recommendation for PFO closure.
For those patients who need or want to avoid PFO, 
the panel judged anticoagulation the best alternative, 
although the evidence regarding stroke reduction was 
of low certainty. The risk of major bleeding probably 
increased with anticoagulation. Although direct antico-
agulants have not been evaluated in PFO, their advan-
tages in terms of convenience may render them, rather 
than warfarin, the best option for those who choose anti-
coagulants.
The main infographic explains the recommendations 
and provides an overview (GRADE summary of findings) 
of the absolute benefits (reduction in recurrent ischaemic 
stroke) and harms of:
•   PFO closure followed by antiplatelet therapy versus 
antiplatelet therapy alone
•   PFO closure followed by antiplatelet therapy versus 
anticoagulants alone
•   Anticoagulants versus antiplatelet therapy.
Estimates of baseline risk for effects come from the 
control arm of the trials, using the median estimate of 
risk where available.1
The panel agreed that, compared with antiplatelet ther-
apy alone, PFO closure followed by antiplatelet therapy:
•   Probably has a large decrease in ischaemic stroke 
(8.7% absolute risk reduction, moderate quality 
evidence) over five years
•   Has a risk of device or procedure related adverse 
events (3.6% absolute risk, high quality evidence) at 
one year
•   Probably has an increase in persistent atrial 
fibrillation or flutter (1.8% absolute risk increase, 
moderate quality evidence) and transient atrial 
fibrillation or flutter (1.2% absolute risk increase, 
moderate quality evidence) at one year
•   Probably has little or no difference in death, major 
bleeding, pulmonary embolism, transient ischaemic 
attack, or systemic embolism (moderate to high 
quality evidence) at five years.
The panel agreed that, compared with anticoagulation, 
PFO closure followed by antiplatelet therapy:
•   May result in little or no difference in ischaemic 
stroke (1.6% absolute risk reduction, low quality 
evidence) at five years
•   Probably decreases major bleeding (2.0% absolute 
risk reduction, moderate quality evidence) at five 
years
•   Has a risk of device or procedure related adverse 
events (3.6% absolute risk, high quality evidence) at 
one year
•   Probably has an increase in persistent atrial 
fibrillation or flutter (1.8% absolute risk increase, 
moderate quality evidence) and transient atrial 
fibrillation or flutter (1.2% absolute risk increase, 
moderate quality evidence) at one year
•   Probably has little or no difference in death, 
pulmonary embolism, transient ischaemic attack, or 
systemic embolism (moderate quality evidence) at 
five years.
HOW THE RECOMMENDATION WAS CREATED
Our international panel included general internists, interventional and non-interventional 
cardiologists, stroke physicians, epidemiologists, methodologists, statisticians, and 
people with personal experience of cryptogenic stroke and patent foramen ovale (PFO). 
They decided on the scope of the recommendation and the outcomes that are most 
important to patients. The panel identified eight patient-important outcomes needed 
to inform the recommendation: non-fatal ischaemic stroke, death, major bleeding, 
pulmonary embolism, serious procedure related or device related adverse events, atrial 
fibrillation, transient ischaemic attack, and systemic embolism.
A parallel team conducted a systematic review addressing the benefits and harms 
of three patient-relevant clinical questions framed by the panel: (a) PFO closure with 
subsequent antiplatelet therapy versus antiplatelet therapy alone, (b) PFO closure with 
subsequent antiplatelet therapy versus anticoagulation, and (c) anticoagulation versus 
antiplatelet therapy.1
Because of a lack of evidence in those with PFO, particularly for the anticoagulation 
option, the panel asked for a summary of the indirect evidence regarding prevention of 
thrombosis from trials of venous thromboembolism and atrial fibrillation.
We also performed a systematic search for evidence regarding patients’ values and 
preferences (see appendix 1 on bmj.com). 
No panel member had financial conflicts of interest; intellectual and professional 
conflicts were minimised and managed (for full summary see appendix 2 on bmj.com).
The panel followed the BMJ Rapid Recommendations procedures for creating a 
trustworthy recommendation,5 28 including using the GRADE approach to critically appraise 
the evidence and create recommendations (see appendix 3 on bmj.com).29 The panel 
considered the balance of benefits, harms, and burdens of the procedure, the quality 
of the evidence for each outcome, typical and expected variations in patient values and 
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The panel agreed that anticoagulation versus antiplate-
let therapy at five years’ duration:
•   May decrease ischaemic stroke (7.1% absolute risk 
reduction over 5 years, low quality evidence)
•   Probably increases major bleeding (1.2% absolute 
risk increase over 5 years, moderate quality 
evidence)
•   Probably has little or no difference in death, 
pulmonary embolism, transient ischaemic attack, or 
systemic embolism (moderate quality evidence).
Values and preferences
PFO closure followed by antiplatelet therapy versus 
antiplatelet therapy alone
Patients for whom anticoagulation is unacceptable or 
contraindicated should consider PFO closure. Our strong 
recommendation for PFO closure for such patients reflects 
the high value they place on avoiding recurrent ischae-
mic stroke. Patients are likely to find absolute reduction 
of stroke with PFO closure of 8.7% in five years impor-
tant. Although 3.6% experience serious device or proce-
dure related adverse events, these do not usually result 
in long term disability, and so we considered them less 
important. Persistent atrial fibrillation after PFO clo-
sure procedure might be a concern; however, the main 
adverse consequence of atrial fibrillation is increased risk 
of stroke, which was already shown to be substantially 
lower in patients randomised to PFO closure.
PFO closure followed by antiplatelet therapy versus 
anticoagulation
The major downsides of PFO closure are the 3.6% inci-
dence of complications from the procedure and the proba-
ble 1.8% absolute increase in persistent atrial fibrillation. 
The major downside of anticoagulation is the probable 
2.0% absolute increase in bleeding risk over five years. 
Other issues to consider are the burden and costs of long 
term anticoagulation. Our weak recommendation for 
PFO closure reflects (in addition to the low certainty in 
the estimates of effect) that most serious complications 
of PFO closure are usually short term, whereas antico-
agulation imposes a long term burden and increased risk 
of major bleeding. Most fully informed patients would 
probably accept the transient risk of major adverse events 
rather than the long term bleeding risk, but a substantial 
minority would probably choose anticoagulation.
Anticoagulation versus antiplatelet therapy
Patients to whom PFO closure is unacceptable or contrain-
dicated have to choose between anticoagulant or anti-
platelet therapy. A typical patient places a high value in a 
possible absolute reduction of stroke with anticoagulation 
of 7.1% over five years and would therefore place higher 
value on the possible benefit of stroke reduction than the 
probable increased risk of major bleeding. A systematic 
review25 and a primary study26 of values and preferences 
on thromboprophylaxis treatment of patients with atrial 
fibrillation showed that, though preferences were highly 
variable, most patients value preventing strokes consider-
ably more than they are concerned about increased risk 
of bleeding. However, there is substantial uncertainty in 
our estimates for stroke reduction—how this uncertainty 
would influence decisions is likely to vary substantially. 
Therefore, we issue a weak recommendation for antico-
agulation. Both options need to be discussed with the 
patient, ideally in a process of shared decision making.
Practical issues and other considerations
Figure 3 outlines the key practical issues for patients and 
clinicians discussing PFO closure and is based on the con-
tent expertise of the panel members; practical issues are 
also accessible, along with the evidence, as decision aids 
PRACTICAL ISSUES
PFO closure Anticoagulant (warafin or direct 
oral anticoagulants (DOAC)) 
TESTS & VISITS
One dose per day
May increase bruising
May increase risk of peptic ulcer
Warafin one dose per day One dose per day antiplatelet therapy
A cardiologist appointment every 1-2
years is suggested 
DOAC once or twice a dose per dayMEDICATION
ROUTINE
Antiplatelet 
Most can take aspirin (a low-cost medication
available without a prescription)
Women who are pregnant or considering 
pregnancy may need to change their
medication
DOACs cost more, but require less 
monitoring
Some foods may increase the risk of stroke
by reducing the effect of warfarin.
Rivaroxaban should be taken with food
Involves low dose radiation exposure to
patient and fetus
Insurance plans may or may not cover 
some or all aspects of the procedure.
May increase risk of bleeding (serious
bleeding or nuisance minor bleeding)
Some medicines may increase the risk of
stroke by reducing the effect of the
anticoagulants
Patient self-monitoring with a small blood
testing device as an alternative to visits to
the blood testing laboratory  
Warafin:
Initial frequent testing required to achieve 
appropriate dose. Periodic testing required 
while taking medication
DOAC:
Dose adjustment mat be required with 
changes in renal function 
PROCEDURE
& DEVICE
Device will be implanted using a catheter, 
inserted through a small cut at the groin, 
with local anaesthesia and moderate
sedation or under general anaesthesia 
The procedure takes under 2 hours. 
In-hospital stay is usually one day or less 
May increase risk of peptic ulcer (due to
antiplatelet therapy) 
Uncertainty about the longevity of the
device
The procedure takes under 2 hours. 
In-hospital stay is usually one day or less 
Most activities can be resumed within a 
few days, with full recovery within a few
weeks.  
Patients should be given a card to carry,
showing the type of device and information













May need to limit activities with high
injury risk or contact
Need to avoid strenuous activity during
recovery
Time to return to work depends on speed
of recovery
Driving may be limited during the first days







Fig 3 |  Practical issues about use of percutaneous closure followed by antiplatelet therapy versus 
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to support shared decision making in MAGICapp. Anti-
platelet therapy or anticoagulation are typically given as 
an oral medication once or twice a day.
Costs and resources
The panel focused on the patient’s perspective rather than 
that of society when formulating the recommendation. 
Because PFO closure is associated with higher costs related 
to the procedure, implementation of this recommendation 
is likely to have an important impact on the costs for health 
funders in the short term. Over the long term, however, 
PFO closure may reduce costs as a result of reduced stroke 
rates and reduction in associated costs.27 Addressing this 
issue formally would require a cost effectiveness analysis.
Uncertainties to be addressed in future research
The key remaining research question is the relative merit 
of PFO closure versus anticoagulation alone. It may also 
be appropriate to conduct further trials of PFO closure 
versus antiplatelet agents alone in those with small PFOs. 
Longer trials are also needed to address the longevity of 
the PFO closure device and ongoing need for monitoring 
of device performance.
Key research questions to inform decision makers and 
future guidelines include:
•   What are the benefits and harms of PFO closure 
versus anticoagulants (including direct oral 
anticoagulants) in patients with PFO and cryptogenic 
stroke?
•   What patient groups are more likely to benefit from 
PFO closure versus medical therapy? (That is, explore 
whether the effect of PFO closure versus medical 
therapy varies with shunt size, presence of atrial 
septal aneurysm, and age.)
•   Which device for PFO closure is best?
•   What is the longevity of the PFO closure device and 
ongoing need for monitoring of device performance?
Updates to this article
The table shows evidence which has emerged since the 
publication of this article. As new evidence is published, 
a group will assess the new evidence and make a judg-
ment on to what extent it is expected to alter the recom-
mendation.
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